The role of glucagon-like peptide-1 receptor agonists in cardiovascular disease prevention in type 2 diabetes mellitus: evidence from the most recent clinical trials

The field of investigation of the prevention of cardiovascular disease (CVD) in type 2 diabetes mellitus (T2DM) has seen a huge proliferation of studies on multiple drug categories and agents in the past decade.